Nicola Fusco

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6750887/publications.pdf

Version: 2024-02-01

140 papers	2,870 citations	186209 28 h-index	243529 44 g-index
143 all docs	143 docs citations	143 times ranked	3089 citing authors

#	Article	IF	Citations
1	Quality of Life Interventions in Breast Cancer Survivors: State of the Art in Targeted Rehabilitation Strategies. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 801-810.	0.9	19
2	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 787-800.	0.9	25
3	Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. BJU International, 2022, 129, 524-533.	1.3	4
4	Pathology after neoadjuvant treatment â€" How to assess residual disease. Breast, 2022, 62, S25-S28.	0.9	18
5	A Model to Predict Upstaging to Invasive Carcinoma in Patients Preoperatively Diagnosed with Low-Grade Ductal Carcinoma In Situ of the Breast. Cancers, 2022, 14, 370.	1.7	6
6	Impact of exercise training on muscle mitochondria modifications in older adults: a systematic review of randomized controlled trials. Aging Clinical and Experimental Research, 2022, 34, 1495-1510.	1.4	25
7	Abstract P4-07-02: Tumor microenvironment characteristics and prognosis in breast cancer during pregnancy: The role of differentially expressed immune-related genes. Cancer Research, 2022, 82, P4-07-02-P4-07-02.	0.4	0
8	Abstract P4-07-01: Loss of HER2 on residual disease after neoadjuvant therapy in HER2-positive early breast cancer: Clinicopathological characteristics and association with outcomes. Cancer Research, 2022, 82, P4-07-01-P4-07-01.	0.4	0
9	Abstract P3-18-08: Feasibility and safety of breast-conserving surgery in early-stage breast cancers during the first trimester of pregnancy. Cancer Research, 2022, 82, P3-18-08-P3-18-08.	0.4	0
10	Abstract P4-10-15: Whole-body vibration combined with physical exercise to treat aromatase inhibitor-induced musculoskeletal symptoms in breast cancer women: Results of a pilot randomized controlled study. Cancer Research, 2022, 82, P4-10-15-P4-10-15.	0.4	0
11	Abstract P4-10-23: Combined analysis of PTEN and routinely assessed biomarkers reveals new high-risk subgroups of HR- or HER2+ breast cancers. Cancer Research, 2022, 82, P4-10-23-P4-10-23.	0.4	0
12	Abstract P1-22-03: Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ. Cancer Research, 2022, 82, P1-22-03-P1-22-03.	0.4	0
13	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. World Journal of Urology, 2022, , 1.	1.2	0
14	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Frontiers in Molecular Biosciences, 2022, 9, 834651.	1.6	63
15	CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. Expert Opinion on Investigational Drugs, 2022, 31, 593-605.	1.9	31
16	Low-risk triple-negative breast cancers: Clinico-pathological and molecular features. Critical Reviews in Oncology/Hematology, 2022, 172, 103643.	2.0	25
17	Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC). Pathologica, 2022, 114, 104-110.	1.3	6
18	Vitamin D Deficiency in Women with Breast Cancer: A Correlation with Osteoporosis? A Machine Learning Approach with Multiple Factor Analysis. Nutrients, 2022, 14, 1586.	1.7	12

#	Article	IF	Citations
19	Lights on HBME-1: the elusive biomarker in thyroid cancer pathology. Journal of Clinical Pathology, 2022, 75, 588-592.	1.0	3
20	FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. Journal of Personalized Medicine, 2022, 12, 750.	1.1	13
21	29P The molecular landscape of breast mucoepidermoid carcinoma. Annals of Oncology, 2022, 33, S136-S137.	0.6	1
22	Gluten Induces Subtle Histological Changes in Duodenal Mucosa of Patients with Non-Coeliac Gluten Sensitivity: A Multicentre Study. Nutrients, 2022, 14, 2487.	1.7	14
23	Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. Journal of Personalized Medicine, 2022, 12, 1073.	1.1	36
24	Axillary Web Syndrome in Breast Cancer Women: What Is the Optimal Rehabilitation Strategy after Surgery? A Systematic Review. Journal of Clinical Medicine, 2022, 11, 3839.	1.0	8
25	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. Molecular Oncology, 2021, 15, 1024-1039.	2.1	21
26	Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the â€œProgrammed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinomaâ€• Journal of Pathology Informatics, 2021, 12, 1.	0.8	22
27	Lymphedema Rehabilitation Using Self-Adaptive Inelastic Compression in Breast Cancer: A Proof-of-Principle Study. Applied Sciences (Switzerland), 2021, 11, 1901.	1.3	13
28	The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization. Diagnostics, 2021, 11, 339.	1.3	46
29	Abstract PS9-36: Exercise therapy to reduce breast cancer fatigue: Results from the EXPECT study. , 2021, , .		0
30	PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Frontiers in Oncology, 2021, 11, 644737.	1.3	70
31	Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. European Journal of Cancer, 2021, 145, 197-209.	1.3	16
32	Mismatch Repair Status Characterization in Oncologic Pathology: Taking Stock of the Real-World Possibilities. Journal of Molecular Pathology, 2021, 2, 93-100.	0.5	10
33	Rethinking the clinical management of volumetric muscle loss in patients with spinal cord injury: Synergy among nutritional supplementation, pharmacotherapy, and rehabilitation. Current Opinion in Pharmacology, 2021, 57, 132-139.	1.7	20
34	How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. Journal of Clinical Medicine, 2021, 10, 1412.	1.0	8
35	10P The clinical actionability of PTEN protein and gene expression analysis in HR- and HER2+ breast cancers. Annals of Oncology, 2021, 32, S25.	0.6	0
36	Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. Cancer Cell International, 2021, 21, 266.	1.8	26

#	Article	IF	Citations
37	The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. Current Drug Targets, 2021, 22, 1021-1033.	1.0	6
38	Comparing prognostic utility between the 8th edition of <scp>TNM</scp> staging system and the lymph node ratio for oral squamous cell carcinoma. Head and Neck, 2021, 43, 2876-2882.	0.9	7
39	Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management. Cells, 2021, 10, 1377.	1.8	35
40	Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in breast cancer patients. Current Opinion in Pharmacology, 2021, 58, 27-34.	1.7	8
41	An EBC/Plasma miRNA Signature Discriminates Lung Adenocarcinomas From Pleural Mesothelioma and Healthy Controls. Frontiers in Oncology, 2021, 11, 643280.	1.3	8
42	Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. Frontiers in Oncology, 2021, 11, 723693.	1.3	8
43	ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. Future Oncology, 2021, 17, 4607-4618.	1.1	4
44	Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients. Frontiers in Oncology, 2021, 11, 735476.	1.3	2
45	PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols. Cancers, 2021, 13, 292.	1.7	36
46	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. World Journal of Urology, 2021, , 1.	1.2	3
47	Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling. BMC Cancer, 2021, 21, 1152.	1.1	9
48	Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials. Frontiers in Oncology, 2021, 11, 829875.	1.3	19
49	Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitorâ€"Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study. Journal of Personalized Medicine, 2021, 11, 1369.	1.1	14
50	Metaplastic breast cancers and triple-negative breast cancers of no special type. European Journal of Cancer Prevention, 2021, Publish Ahead of Print, .	0.6	7
51	Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. Histology and Histopathology, 2021, , 18376.	0.5	11
52	Myostatin as a potential biomarker to monitor sarcopenia in hip fracture patients undergoing a multidisciplinary rehabilitation and nutritional treatment: a preliminary study. Aging Clinical and Experimental Research, 2020, 32, 959-962.	1.4	39
53	Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients. Lung Cancer, 2020, 150, 53-61.	0.9	36
54	Editorial: Quality of Life in Breast Cancer Patients and Survivors. Frontiers in Oncology, 2020, 10, 620574.	1.3	33

#	Article	IF	Citations
55	Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers. Translational Cancer Research, 2020, 9, 4060-4064.	0.4	24
56	Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study. Frontiers in Oncology, 2020, 10, 556718.	1.3	49
57	Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. Cancer Treatment Reviews, 2020, 90, 102089.	3.4	27
58	Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing. Gastrointestinal Disorders, 2020, 2, 341-352.	0.4	7
59	Pharmacological management of male breast cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 1493-1504.	0.9	3
60	Bone Muscle Crosstalk in Spinal Cord Injuries: Pathophysiology and Implications for Patientsâ€™ Quality of Life. Current Osteoporosis Reports, 2020, 18, 422-431.	1.5	20
61	Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review. Cancers, 2020, 12, 1598.	1.7	37
62	PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. Genes, 2020, 11, 719.	1.0	67
63	Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. Cancers, 2020, 12, 1800.	1.7	12
64	RE: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. Breast Cancer Research and Treatment, 2020, 180, 265-266.	1.1	7
65	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 1461.	1.8	25
66	Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis. Journal of Visualized Experiments, 2020, , .	0.2	29
67	Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options . Cancer Management and Research, 2020, Volume 12, 675-686.	0.9	27
68	Spinal Cord Injury as a Model of Bone-Muscle Interactions: Therapeutic Implications From in vitro and in vivo Studies. Frontiers in Endocrinology, 2020, 11, 204.	1.5	23
69	Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema. Frontiers in Oncology, 2020, 10, 422.	1.3	17
70	Three-dimensional laser scanning as a reliable and reproducible diagnostic tool in breast cancer related lymphedema rehabilitation: a proof-of-principle study. European Review for Medical and Pharmacological Sciences, 2020, 24, 4476-4485.	0.5	28
71	Axillary web syndrome in women after breast cancer surgery referred to an Oncological Rehabilitation Unit: which are the main risk factors? A retrospective case-control study. European Review for Medical and Pharmacological Sciences, 2020, 24, 8028-8035.	0.5	29
72	Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?. Ecancermedicalscience, 2020, 14, 1150.	0.6	27

#	Article	IF	Citations
73	Tubular Adenoma of the Breast. Encyclopedia of Pathology, 2020, , 379-384.	0.0	0
74	Abstract P2-05-03: Integrated analysis of mismatch repair, PD-L1, and immune microenvironment status in pregnancy-associated breast cancers. , 2020, , .		0
75	Chondroid Differentiation in Thyroid Nodular Hyperplasia: An Innocent Bystander?. International Journal of Surgical Pathology, 2019, 27, 274-274.	0.4	1
76	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5452.	1.8	53
77	The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. BioMed Research International, 2019, 2019, 1-7.	0.9	20
78	Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab. Journal of Clinical Medicine, 2019, 8, 138.	1.0	28
79	Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors. International Journal of Molecular Sciences, 2019, 20, 510.	1.8	25
80	Diagnostic challenge of intrathoracic tissue misplacements: a thymic choristoma in a fetal lung. Thorax, 2019, 74, 624-624.	2.7	1
81	The conundrum of breast chondrolipoma: Heterotopic, metaplastic, or neoplastic lesion?. Breast Journal, 2019, 25, 733-734.	0.4	2
82	A novel integrated platform for the identification of surgical margins in oral squamous cell carcinoma: results from a prospective single-institution series. BMC Cancer, 2019, 19, 467.	1.1	4
83	TdT expression in germ cell tumours: a possible immunohistochemical cross-reaction and diagnostic pitfall. Journal of Clinical Pathology, 2019, 72, 536-541.	1.0	6
84	The Genetic Landscape of Human Glioblastoma and Matched Primary Cancer Stem Cells Reveals Intratumour Similarity and Intertumour Heterogeneity. Stem Cells International, 2019, 2019, 1-12.	1.2	29
85	NF1 Alterations are Linked to Increased HER2 Expression in Breast Cancerâ€"Letter. Cancer Prevention Research, 2019, 12, 195-196.	0.7	3
86	PWE-035â€...Global translation of coeliac disease histology and other gluten related microenteropathy. , 2019, , .		0
87	Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All?. Advances in Anatomic Pathology, 2019, 26, 270-279.	2.4	29
88	Tackling the diversity of breast cancer related lymphedema: Perspectives on diagnosis, risk assessment, and clinical management. Breast, 2019, 44, 15-23.	0.9	54
89	Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability. Thyroid, 2019, 29, 237-251.	2.4	31
90	Columnar Cell Lesion and Apocrine Hyperplasia of the Breast: Is There a Common Origin? The Role of Prolactin-induced Protein. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 508-514.	0.6	11

#	Article	IF	Citations
91	Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging. Journal of Proteomics, 2019, 191, 114-123.	1.2	37
92	Abstract P1-12-09: Proposal for integrating the pathologic assessment of lymphovascular invasion and extranodal tumor extension in breast cancer-related lymphedema clinical management. , 2019, , .		0
93	Abstract P3-07-02: Metaplastic breast carcinomas and uterine carcinosarcomas are histologically and genetically related. , 2019, , .		0
94	Abstract P2-08-21: Mismatch repair protein loss is a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability. , 2019, , .		0
95	Rathke's cleft cyst associated with pituitary granulomatosis with polyangiitis: An unusual combination of hypothalamus-pituitary region pathologies. Radiology Case Reports, 2018, 13, 233-236.	0.2	0
96	Effects of hypnosis on the relative parasympathetic tone assessed by ANI (Analgesia/Nociception Index) in healthy volunteers: a prospective observational study. Journal of Clinical Monitoring and Computing, 2018, 32, 487-492.	0.7	20
97	MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYBâ€“NFIB fusion gene. Journal of Pathology, 2018, 244, 143-150.	2.1	74
98	Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability. JNCI Cancer Spectrum, 2018, 2, pky056.	1.4	71
99	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget, 2018, 9, 20617-20630.	0.8	36
100	Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma. International Journal of Molecular Sciences, 2018, 19, 3014.	1.8	12
101	Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up. BMC Cancer, 2018, 18, 935.	1.1	32
102	Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal. Journal of Thoracic Oncology, 2018, 13, 1750-1761.	0.5	27
103	CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoidsÂ- a short report. Cellular Oncology (Dordrecht), 2018, 41, 687-691.	2.1	2
104	Tubular Adenoma of the Breast. Encyclopedia of Pathology, 2018, , 1-6.	0.0	0
105	Lymphovascular invasion and extranodal tumor extension as risk indicators of breast cancer-related lymphedema.. Journal of Clinical Oncology, 2018, 36, e12609-e12609.	0.8	0
106	Recurrent <scp>NAB</scp>2â€“<scp>STAT</scp>6 gene fusions and oestrogen receptorâ€Î± expression in pulmonary adenofibromas. Histopathology, 2017, 70, 906-917.	1.6	29
107	Clonal reticulohistiocytosis of the skin and bone marrow associated with systemic mastocytosis and acute myeloid leukaemia. Histopathology, 2017, 70, 1000-1008.	1.6	8
108	Cofilin is a cAMP effector in mediating actin cytoskeleton reorganization and steroidogenesis in mouse and human adrenocortical tumor cells. Cancer Letters, 2017, 406, 54-63.	3.2	8

#	Article	IF	Citations
109	Hibernation in Unusual Places: A Pure Typical Hibernoma of the Breast. Breast Journal, 2017, 23, 104-105.	0.4	2
110	Premalignant and Pre-invasive Lesions of the Breast. , 2017, , 103-120.		2
111	Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers. Journal of Visualized Experiments, 2017, , .	0.2	11
112	Looking for sputum biomarkers in lung cancer secondary prevention: where are we now?. Journal of Thoracic Disease, 2017, 9, 4277-4279.	0.6	3
113	Circulating and tissue biomarkers in early-stage non-small. Ecancermedicalscience, 2017, 11, 717.	0.6	19
114	Abstract P5-06-07: PTEN immunohistochemistry is a predictor of mismatch repair status in breast cancer. , 2017, , .		0
115	CT-guided fine-needle aspiration biopsy of pulmonary lesions under 15 mm of diameter: results on 68 consecutive patients. Annals of Oncology, 2016, 27, iv12.	0.6	0
116	Autoimmune Hepatitis: An Uncommon Presentation of Thymoma. Tumori, 2016, 102, S40-S42.	0.6	6
117	Lack of <scp>PRKD</scp>2 and <scp>PRKD</scp>3 kinase domain somatic mutations in <scp>PRKD</scp>1 wildâ€type classic polymorphous lowâ€grade adenocarcinomas of the salivary gland. Histopathology, 2016, 68, 1055-1062.	1.6	23
118	Microglandular adenosis associated with tripleâ€negative breast cancer is a neoplastic lesion of tripleâ€negative phenotype harbouring <scp>TP53</scp> somatic mutations. Journal of Pathology, 2016, 238, 677-688.	2.1	52
119	Rediscovering Secondary Tumors of the Prostate in the Molecular Era. Advances in Anatomic Pathology, 2016, 23, 170-179.	2.4	7
120	Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. Histopathology, 2016, 68, 262-271.	1.6	22
121	Approaching the histodynamics of celiac disease in modern times: the need of going beyond the dogmas. Digestive and Liver Disease, 2016, 48, 449-450.	0.4	1
122	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. Modern Pathology, 2016, 29, 1292-1305.	2.9	68
123	Therapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy. Molecular Therapy, 2016, 24, 1898-1912.	3.7	37
124	The Genomic Landscape of Male Breast Cancers. Clinical Cancer Research, 2016, 22, 4045-4056.	3.2	119
125	HER2aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. World Journal of Gastroenterology, 2016, 22, 7926.	1.4	43
126	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesisâ€generating study. Journal of Pathology, 2015, 237, 166-178.	2.1	53

#	Article	IF	Citations
127	â€œGiants in a Microcosmâ€• International Journal of Surgical Pathology, 2015, 23, 654-655.	0.4	3
128	MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast. Histopathology, 2015, 67, 719-729.	1.6	78
129	The Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular Correlations. PLoS ONE, 2015, 10, e0144923.	1.1	12
130	The Birth of an Adenoid Cystic Carcinoma. International Journal of Surgical Pathology, 2015, 23, 26-27.	0.4	9
131	Basal Cell Carcinoma and Seborrheic Keratosis. International Journal of Surgical Pathology, 2015, 23, 464-464.	0.4	2
132	Abstract S6-06: The genomic landscape of male breast cancers. , 2015, , .		1
133	Role of multidisciplinary approach in a case of Langerhans cell histiocytosis with initial periodontal manifestations. International Journal of Clinical and Experimental Pathology, 2015, 8, 13539-45.	0.5	6
134	Expression and Clinical Significance of the Autophagy Proteins BECLIN 1 and LC3 in Ovarian Cancer. BioMed Research International, 2014, 2014, 1-10.	0.9	67
135	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nature Genetics, 2014, 46, 1166-1169.	9.4	188
136	HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Modern Pathology, 2013, 26, 816-824.	2.9	57
137	Juxtaglomerular Cell Tumor: Multicentric Synchronous Disease Associated With Paraneoplastic Syndrome. Journal of Clinical Oncology, 2013, 31, e240-e242.	0.8	13
138	High Expression of Cathepsin D in Non-Hodgkinâ€™s Lymphomas Negatively Impacts on Clinical Outcome. Disease Markers, 2010, 28, 167-183.	0.6	5
139	High expression of cathepsin D in non-Hodgkin's lymphomas negatively impacts on clinical outcome. Disease Markers, 2010, 28, 167-83.	0.6	3
140	Hereditary gastric and breast cancer syndromes with lung metastasis: narrative review of molecular and clinical insights. AME Surgical Journal, 0, .	0.0	0